KPTI Karyopharm Therapeutics Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1503802 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.8%
TTM net income YoY-81.9%
TTM EPS YoY-2.7%
Revenue 3-yr CAGR0.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-56.2%
Net margin-153.3%
FCF margin—
EBITDA margin-56.1%
Returns
ROE—
ROA-207.9%
ROIC (approx.)—
Asset turnover1.36x
Leverage & solvency
Liabilities / assets396.6%
Debt / equity—
Current ratio0.79x
Interest coverage-1.67x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-147.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $146.07M | $145.24M |
| R&D expense | $125.62M | $143.23M |
| SG&A expense | $105.21M | $115.44M |
| Operating income | -$90.71M | -$119.44M |
| Interest expense | $45.85M | $37.42M |
| Pretax income | -$196.00M | -$76.36M |
| Income tax | $43,000 | $57,000 |
| Net income | -$196.04M | -$76.42M |
| EBITDA | -$90.41M | -$119.10M |
| EPS (basic) | -17.93 | -9.41 |
| EPS (diluted) | -17.93 | -14.00 |
| Weighted avg. shares (diluted) | 10,935 | 8,455 |
| Balance sheet | ||
| Cash & equivalents | $60.54M | $62.81M |
| Short-term investments | $3.20M | $46.24M |
| Receivables | $26.18M | $30.77M |
| Inventory | $4.04M | $4.74M |
| Current assets | $103.15M | $156.46M |
| PP&E, net | $104,000 | $400,000 |
| Total assets | $108.42M | $164.42M |
| Current liabilities | $92.06M | $92.26M |
| Total liabilities | $401.34M | $350.44M |
| Shareholders' equity | -$292.93M | -$186.02M |
| Shares outstanding | 18.31M | 8.41M |
| Cash flow statement | ||
| Operating cash flow | -$75.37M | -$127.49M |
| Capital expenditure | $0 | $142,000 |
| Free cash flow | -$75.37M | -$127.63M |
| Investing cash flow | $43.38M | $95.47M |
| Financing cash flow | $30.05M | $41.65M |
| Depreciation & amortization | $296,000 | $340,000 |
| Stock-based compensation | $14.05M | $18.43M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.